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Abstract
Background There are an increasing number of studies
using simulation models to conduct cost-effectiveness
analyses for type 2 diabetes mellitus.
Objective To evaluate the relationship between improve-
ments in glycosylated haemoglobin (HbA1c) and simulated
health outcomes in type 2 diabetes cost-effectiveness studies.
Methods A systematic review was conducted on MEDLINE
and EMBASE to collect cost-effectiveness studies using type
2 diabetes simulation models that reported modelled health
outcomes of blood glucose-related interventions in terms of
quality-adjusted life-years (QALYs) or life expectancy (LE).
The data extracted included information used to characterise
the study cohort, the intervention’s treatment effects on risk
factors and model outcomes. Linear regressions were used to
test the relationship between the difference in HbA1c
(DHbA1c) and incremental QALYs (DQALYs) or LE (DLE)
of intervention and control groups. The ratio between the
DQALYs and DLE was calculated and a scatterplot between
the ratio and DHbA1c was used to explore the relationship
between these two.
Results Seventy-six studies were included in this research,
contributing to 124 pair of comparators. The pooled
regressions indicated that the marginal effect of a 1%
HbA1c decrease in intervention resulted in an increase in
life-time QALYs and LE of 0.371 (95% confidence interval
0.286–0.456) and 0.642 (95% CI 0.494–0.790), respec-
tively. No evidence of heterogeneity between models was
found. An inverse exponential relationship was found and
fitted between the ratio (DQALY/DLE) and DHbA1c.
Conclusion There is a consistent relationship between
DHbA1c and DQALYs or DLE in cost-effectiveness analyses
using type 2 diabetes simulation models. This relationship can
be used as a diagnostic tool for decision makers.
Key Points for Decision Makers
There is a consistent relationship between treatment-
effect assumptions on glycosylated haemoglobin and
simulated outcomes in type 2 diabetes mellitus cost-
effectiveness studies.
A 1% glycosylated haemoglobin decrease in
intervention results in an increase in life-time
quality-adjusted life years and life expectancy of
0.371 and 0.642, respectively.
This relationship can be used as a benchmark to
identify studies deviating from others, and generate
preliminary long-term effectiveness predictions
when insufficient resources are available to use a
simulation model.
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Simulation modelling is a useful tool in health economic
evaluation, especially for interventions targeted at treating
chronic diseases such as diabetes mellitus. Clinical trials of
new therapies and behavioural interventions in type 2
diabetes often involve estimation on changes in interme-
diate-risk factors such as glycosylated haemoglobin
(HbA1c) [1, 2]. For these interventions to be evaluated
using common health economic outcomes such as quality-
adjusted life-years (QALYs), the potential benefits of
observed improvements in metabolic control need to be
extrapolated over longer time periods to capture impacts on
the rates of complications of diabetes as well as mortality.
There is a long history in the use of simulation models to
evaluate interventions for people with type 2 diabetes. The
first simulation model for type 2 diabetes was built in 1997 by
Eastman et al. [3, 4], which was based on clinical data from
both type 2 and type 1 diabetes. Many models have been
developed since then [5], and while many are based on the
United Kingdom Prospective Diabetes Study (UKPDS) Out-
comes Model [6], there are differences in terms of model
structure, particularly when they incorporate additional epi-
demiological and trial evidence to capture additional com-
plications (e.g. impact of hypoglycaemia). A common feature
of all these models is that they extrapolate changes in inter-
mediate outcomes such as HbA1c to metrics such as QALYs
or life expectancy (LE), which are most commonly used to
capture outcomes in economic evaluations.
While most diabetes simulation models have been
developed independently, the field has benefited from the
diabetes simulation modelling conference ‘Mount Hood
Diabetes Challenge’, which has been regularly held since
2000 to compare and contrast the outputs of models in a set
series of simulations [7]. The last Mount Hood Diabetes
Challenge meeting was held in 2014 and developers of 11
type 2 diabetes models participated, highlighting the
development of simulation modelling in type 2 diabetes in
recent years [8]. Diabetes simulation models are now
widely used in cost-effectiveness studies and play an
important role in defining clinical guidelines and the
evaluation of new drugs [9].
Former reviews in type 2 diabetes cost-effectiveness
studies have focused on summarising and describing the
characteristics of different models [5, 10]. Currently, there are
no studies that use quantitative techniques to evaluate the
relationship between treatment-effect assumptions (e.g. a
reduction in the level of HbA1c) and simulated outcomes (e.g.
a gain in QALYs or LE). In this article, we systematically
review cost-effectiveness studies of glycaemic control inter-
ventions that use type 2 diabetes simulation models to esti-
mate long-term outcomes of QALYs or LE. Using data
extracted from those studies, we use regression analysis to
estimate the relationship between initial changes in HbA1c
following the commencement of an intervention and model
outputs. The objective of this research is to explore whether
there is a consistent relationship between a widely reported
intermediate outcome that is often used as an input in simu-
lation models and model outputs across type 2 diabetes cost-
effectiveness studies, and across different models.
2 Methods
2.1 Data Sources and Searches
We reviewed studies that involved use of a type 2 diabetes
simulation model to inform a cost-effectiveness analysis
(CEA) or cost-utility analysis (CUA) of blood glucose-
lowering interventions that measured a change in HbA1c.
All ten type 2 diabetes models that participated in the
fourth (2004) or fifth (2010) Mount Hood Diabetes Chal-
lenge were considered to be eligible for inclusion in this
study [11, 12], including the UKPDS Outcomes Model,
IMS CORE Diabetes Model, Cardiff Model, Sheffield
Diabetes Model, EAGLE Model, CDC-RTI Diabetes Cost-
effectiveness Model, Archimedes Model, Michigan Model,
ECHO-T2DM and the Evidence-Based Medicine Integra-
tor Simulator. The UKPDS risk engine participated in the
fourth Mount Hood Diabetes Challenge but was not
included in this study as it does not quantify lifetime out-
comes in terms of QALYs or LE [13]. Descriptions and
further details of these models can be found in the Mount
Hood Diabetes Challenge reports [11, 12].
The Preferred Reporting Items for Systematic Reviews
and Meta-analyses recommendations and checklist were
followed to conduct the systematic review [14]. Studies
were identified by searching electronic databases, supple-
mented by scanning citations of the original publication of
the ten targeted models and finally by contacting the model
groups individually. The search was applied in two elec-
tronic databases, MEDLINE (1946 to present) and
EMBASE (1947 to present) on Ovid. The subject heading
‘Diabetes Mellitus, Type2’ and other search terms includ-
ing T2DM, cost effective*, cost utilit*, long term out-
come*, long term consequence*, health economic*, health
evaluation, economic evaluation, model*, simula*,
QALY*, life year* and LE were used (see Supplementary
Material 1 for full details on the search strategy).
2.2 Study Selection
The search was completed on 1 June, 2015 and included all
published studies prior to that date. The inclusion criteria
were as follows:
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• language in English;
• reported outcomes were part of a CEA or CUA;
• the study simulated outcomes based on one of the ten
diabetes models mentioned above;
• the population simulated in the model involved only
people with type 2 diabetes;
• the intervention focused on improvements in blood
glucose control;
• the primary treatment effect being modelled was the
difference in HbA1c;
• the study reported long-term (C20 years) outcomes in
either QALYs or LE.
Studies were excluded if:
• language was not English;
• it did not conduct CEA or CUA;
• it used other established models or self-built models;
• it included other populations (type 1 diabetes, pre-
diabetes);
• the intervention did not focus on improvements in
blood glucose control or was a multifactorial
intervention;
• HbA1c was not used as the treatment effect or there was
no difference in the reduction of HbA1c levels between
the intervention and control group;
• it did not report QALYs or LE as outcomes;
• the outcomes were estimated only in the short term;
• no discount rate was reported for the outcomes;
• the study did not report the data necessary for this
research (difference in HbA1c and incremental QALYs/
LE).
Two reviewers (XH and LS) separately reviewed the
studies by reading their abstracts and full texts. A third
reviewer’s (PC) opinion was considered when there was a
conflict of opinion between the first two. All but one of the
Mount Hood modelling groups were contacted through
email with a request for publications or a list of studies
fitting our criteria (the EAGLE model group was excluded
as no current contact details are available for its develop-
ers). A published model description paper was found for
eight models (UKPDS [6], CORE [15], Cardiff [16],
EAGLE [17], CDC [18], Archimedes [19], Michigan [20]
and ECHO [21]). Studies that cited the aforementioned
papers were scanned in Google Scholar, Web of Science
and PubMed and added if they met our inclusion criteria.
2.3 Data Extraction
The intervention’s treatment effects on risk factors were
extracted from each included study. Risk factors include
HbA1c (%), body mass index (BMI), systolic blood pres-
sure (mm Hg), total cholesterol (mmol/L) and
hypoglycaemic events (patient-year). The treatment effect
is the difference in effect between the two groups. In some
studies, this difference is directly reported; in other studies,
they report the change in risk factors separately for each
group. In the latter situation, we calculated the treatment
effect by subtracting the two change values. Proper trans-
formation was made when risk factors were not reported in
the required unit (1 mmol/L = 38.6 mg/dL for total
cholesterol). For eight studies [22–29], that only reported
change in weight but not BMI as a treatment effect, the
change in BMI was imputed using the cohort baseline
height or 1.67 m as the default height (the average height
for patients in the UKPDS [30]) if the cohort height was
not reported in the study.
The model outcomes of interest in this study are QALYs
and LE. Differences in QALYs (DQALYs) and LE (DLE)
between the two groups in the base case were extracted
from each study, as well as the discount rate used for the
base case. Differences in undiscounted outcomes were also
collected if they were available in the sensitivity analysis.
We also extracted summary statistics of the study cohort,
including the year of the study, comparators, cohort base-
line age, diabetes duration and post-treatment HbA1c level
in the control group. For studies that evaluated multiple
comparisons, data of all these comparisons were included
and collected. Data extraction was conducted indepen-
dently by two reviewers (XH and LS). Disagreements were
resolved through discussion.
2.4 Data Synthesis and Analysis
We conducted a basic descriptive analysis on the type of
interventions, comparators and risk factors involved to
summarise the identified studies. All analyses were con-
ducted on undiscounted outcomes. Where studies only
reported discounted outcomes, estimates of the undis-
counted outcomes were imputed based on an algorithm that
was developed from studies that reported both discounted
and undiscounted outcomes (see Supplementary Material 4
for further description).
The relationship between DHbA1c and the difference in
outcomes for comparators was examined using scatterplot
and linear regression. Univariate regression was conducted
initially for studies using different models separately.
Then, a multivariable regression analysis was undertaken
for all the studies. We used eight independent variables in
the multivariable regression: difference in HbA1c, BMI,
systolic blood pressure, total cholesterol, hypoglycaemic
events; cohort baseline age; diabetes duration and post-
treatment HbA1c level in the control group. Studies lacking
information on these variables were excluded from the
multivariable regression. Linearity of explanatory variables
was checked and confirmed using multivariable fractional
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polynomials [31]. Interactions of each explanatory variable
with HbA1c were checked by adding a multiplicative term
into the regressions and no interactions were found. Sta-
tistical analysis took into account clustering by using the
clustered robust standard errors method, owing to multiple
comparisons coming from the same study. Before pooling
studies that used different models together, the interaction
effect between model type and DHbA1c on DQALYs and
DLE was tested.
To test the coefficients of DHbA1c across multivariable
regressions involving QALYs and LE, the equations were
jointly estimated using STATA command MVREG
(StataCorp LP, College Station, TX, USA) [32] and a Chi-
square test was made. A significant difference between the
two coefficients was confirmed. The ratio between DQA-
LYs and DLE was then calculated and a scatterplot
between the ratio and DHbA1c was built to explore the
relationship between these two. Logarithm transformation
of the ratio was made in an effort to fit the scatterplot. All
statistical analyses were conducted using STATA 13.1 IC
(StataCorp LP, College Station, TX, USA).
3 Results
3.1 Summary of the Studies Included in the Analysis
Two hundred and eighty-eight studies were identified
after applying our search strategy on MEDLINE and
EMBASE and after abstract and full-text review, 65
publications were included in our study, as shown in
Fig. 1. Our e-mail request resulted in ten extra studies,
one from the ECHO model and nine using the CORE
model and one additional study using the UKPDS Out-
comes Model was identified through citation scanning. In
total, 76 studies were included in this research, resulting
in 124 pair of comparators [18, 22, 23, 25–29,
35–42, 44–103].
Literature search: Medline, 
EMBASE
Search results combined (n=288)




Didn’t conduct CEA or CUA(n=25)
Included other populations (n=48)
Intervention not focused on  blood glucose (n=62)
Didn’t report QALY/LE as outcome(n=1)






Did not conduct CEA or CUA(n=5)
Included other populations (n=1)
Intervention not focused on  blood glucose (n=3)
No difference in HbA1c (n=2)
No discount rate reported for the outcomes(n=1)
Short time horizon(n=2)





























Fig. 1 Flow diagram of publications included and excluded from the review. CEA cost-effectiveness analysis, CUA cost-utility analysis, HbA1c
glycosylated haemoglobin, LE life expectancy, QALY quality-adjusted life-year, UKPDS United Kingdom Prospective Diabetes Study
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A summary of these studies can be found in Supple-
mentary Material 2. Of the included studies, 43.4%
evaluated the cost effectiveness of oral therapy drugs,
29.0% for insulin, 23.7% for management interventions
and 3.9% (three studies) were not intervention specific. In
addition, 22.4% of all included studies used HbA1c as the
only treatment effect of the intervention. In recent years,
other treatment effects such as BMI, blood pressure,
hypoglycaemic events and lipid levels have increasingly
been used, mainly in studies that evaluate cost effective-
ness of new oral therapies; BMI and hypoglycaemic
events are the two common effects besides HbA1c in
insulin evaluation studies (see Figures S1 and S2 in
Supplementary Material 3).
3.2 Relationship between Difference in HbA1c
and the Outcomes
For the 76 studies included in this analysis, 75 reported
QALYs as their model outcome and 59 studies reported LE
as a simulation outcome. Forty-five studies (59.2%)
reported undiscounted QALYs in their sensitivity analysis.
The ratio values used for different discount rates to cal-
culate undiscounted outcomes for the rest of the 31 studies
(59/124 data points) can be found in Supplementary
Material 4. One study [33] with four comparators was
excluded from the QALYs regression analysis because it
involved a large utility change in year 1 (0.152–0.312) as a
direct treatment effect stemming from the intervention.
This makes the relationship between HbA1c and QALY
gain in this study not comparable to others, as other studies
generally assumed changes in utility were mediated
through changes in other risk factors such as BMI.
As only 19 studies used models other than the CORE
model, those studies were combined together for the fol-
lowing regression analysis. Figure 2 depicts the scatter-
plots of differences in HbA1c and the difference in QALYs
or LE in studies that use the CORE model and other
models. A linear relationship could be found in these
scatterplots.
The mean difference in HbA1c is 0.51%, while the mean
increment in QALYs and LE are 0.409 and 0.389,
respectively. The univariate regression results (Table 1)
showed that for studies that used the CORE model, every
1% decrease in HbA1c from the intervention resulted in an
increase of 0.455 and 0.808 for QALYs and LE, respec-
tively. For studies that used the other models, every 1%
decrease in HbA1c from the intervention resulted in a 0.352
increase in QALYs and a 0.696 increase in LE. No inter-
action effect was found between the models and a change
in HbA1c (p = 0.557 for QALY; p = 0.234 for LE). After
pooling all studies together, every 1% decrease in HbA1c
from the intervention resulted in a 0.434 increase in
QALYs and a 0.794 increase in LE. All the coefficients for
HbA1c are significant at the 5% level.
Six studies were excluded from the multivariable
regression because of a lack of information on age, dia-
betes duration or post-treatment HbA1c level in the control
group [18, 38–42]. After controlling for all five risk factors
and age, diabetes duration and post-treatment HbA1c level


























































Fig. 2 Relationships between
DHbA1c and DQALYs or DLE,
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in the control group and pooling all studies together,
DHbA1c, DBMI, Dblood pressure and Dhypoglycaemia
events were the four variables with significant coefficients
for DQALYs. Every 1% decrease in HbA1c from the
intervention resulted in a 0.371 increase in QALYs.
DHbA1c, Dblood pressure and Dtotal cholesterol were
significant coefficients in the multivariable regression for
LE. Every 1% decrease in HbA1c from the intervention
resulted in a 0.642 increase in LE (Table 2).
The relationship between DHbA1c and the ratio of
DQALYs and DLE can be found in Fig. 3. When the dif-
ference in HbA1c is small, the ratio between DQALYs and
DLE increases dramatically. By transforming the depen-
dent variable into ln(y), an inverse exponential relationship
was found and fitted to the scatter graph.
4 Discussion
This study used regression analysis to estimate the associ-
ation between changes in risk factors (e.g. HbA1c), which
are common inputs for simulation models, and the esti-
mated outcomes. The analysis is based on data from 76
studies obtained through a systematic review of published
cost-effectiveness studies of blood glucose-lowering inter-
ventions for people with type 2 diabetes. Based on multiple
linear regression that adjusted for a variety of metabolic risk
factors, it found that the marginal effect of a 1% HbA1c
decrease could result in life-time increases in QALYs and
LE of 0.371 and 0.642, respectively. There was no evidence
of heterogeneity between models. Studies reporting small
differences in HbA1c tend to report larger gains for QALYs
than LE, which implies that when the treatment effect on
HbA1c is limited, the increase in QALYs mainly comes
from utility gain, rather than longer life-years.
In this study, we mainly focus on the treatment effect of
changes in HbA1c, as it is used in almost all analyses of
blood glucose control interventions and is an input for all
diabetes simulation models. Our review result suggests that
recent economic evaluations of blood glucose-lowering
interventions now use a wider variety of risk factors. For
example, hypoglycaemic events, which have been incor-
porated into several models (CORE, Cardiff and ECHO) as
an outcome of interest, were not captured in economic
evaluations prior to 2006, but influence the outcomes of
over 60% of the model simulations of blood glucose low-
ering in published studies during 2013–15 (Figure S1 in the
Supplemental Material). We included these treatment
effects into our multivariable regressions and found a sig-
nificant relationship between them and model outputs as
well. Furthermore, the relationship between the ratio of
increase in QALYs and LE and a difference in HbA1c
could be explained by the treatment effect on BMI and
hypoglycaemia events. In addition to the impact on com-
plications and death, the decrease in BMI and avoidance in
adverse events themselves could also increase people’s
quality of life [34] and appear to play a significant role in
the outcomes of some recent economic evaluations of
blood glucose control therapies [35, 36].
There are several potential practical applications of the
relationship between a change in initial HbA1c and model
outcomes found in this study. First, it can be used as a
diagnostic tool or benchmark for decision makers, enabling
them to identify analyses that deviate from the general trend
and investigate whether there are other factors that may have
led to the discrepancy and whether they are reasonable.
Second, with limited information and resources to run a
diabetes simulation model, the regression estimated in this
study can be used to give a rough prediction of the long-term
effectiveness that could be expected from an intervention in
its early stages. In addition, beyond the specific results, this
study provides a potential methodology for a meta-analytic
approach to combining the results of cost-effectiveness
studies based on simulated outcomes in the future.
Table 1 Results of univariate
regression between DHbA1c and
DQALY as well as DLE
HbA1c coef. Lower CI Upper CI P value R
2
Studies using the CORE model
QALY (n = 98) 0.455 0.277 0.633 \0.001* 0.336
LE (n = 74) 0.808 0.503 1.113 \0.001* 0.687
Studies using other models
QALY (n = 21) 0.352 0.054 0.650 0.023* 0.293
LE (n = 14) 0.696 0.144 1.248 0.018* 0.306
Pooled
QALY (n = 119) 0.434 0.279 0.589 \0.001* 0.341
LE (n = 88) 0.794 0.500 1.088 \0.001* 0.656
CI confidence interval, HbA1c glycosylated haemoglobin, LE life expectancy, QALY quality-adjusted life-
year, coef. co-efficient
* Significant at 5% level
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This study has also highlighted inconsistencies in the
reporting of assumptions regarding the treatment effect and
in results of model simulations. To make cost-effectiveness
simulation results transparent, the effect of treatment on all
major risk factors should be reported over time. Currently,
there is no standard way of reporting assumptions regard-
ing the duration of an intervention effect on risk factors
(e.g. some studies report an annual decay [37], while others
a change at some future time [26]). The lack of consistent
reporting has made it hard for us to incorporate this
information into our regressions at this stage, thus we have
been limited to using the initial change in HbA1c and other
risk factors in our regression models. Three studies were
excluded because the initial change in risk factors was not
clearly reported. However, the main issue with the
reporting of outcomes was that 40% of studies included in
this analysis did not report their undiscounted results.
Studies from different countries usually use different dis-
count rates for their base case results, which makes the
comparison between studies difficult to conduct. To
address this issue, we calculated an average ratio between
discounted and undiscounted DQALYs and used this to
infer undiscounted outcomes when these were not reported.
Basic cohort characteristics (age, duration of diabetes,
proportion of male, ethnicity and other baseline risk fac-
tors) and model assumptions (time horizon) were also
sometimes not reported. In this analysis, six studies were
excluded from the multivariable regression because of a
lack of information on age, diabetes duration or post-
treatment HbA1c level in the control group [18, 38–42].
There is a clear need for general reporting standards of
diabetes cost-effectiveness studies to be developed to
promote transparency and facilitate future model compar-
isons. A starting point for this is the use of the Consolidated
Health Economic Evaluation Reporting Standards [43].
This study is subject to a number of limitations. First,
the difference in HbA1c collected in this study is the initial
difference between two simulated cohorts, which is often
the only measure of glycaemia that many simulation
Table 2 Results of
multivariable regression
Coef. Lower CI Upper CI P value
For DQALYs (n = 108)
HbA1c (%) 0.371 0.286 0.456 \0.001*
BMI (kg/m2) 0.088 0.048 0.129 \0.001*
Systolic blood pressure (mmHg) 0.067 0.019 0.115 0.007*
Hypoglycaemic event (patient-year) 0.038 0.024 0.052 \0.001*
Total cholesterol (mmol/L) 0.227 -0.040 0.493 0.094
Age -0.008 -0.020 0.005 0.225
Duration -0.005 -0.017 0.006 0.354
Post-treatment HbA1c (%) 0.019 -0.041 0.079 0.523
For DLE (n = 78)
HbA1c (%) 0.642 0.494 0.790 \0.001*
BMI (kg/m2) -0.003 -0.055 0.049 0.908
Systolic blood pressure (mmHg) 0.073 0.018 0.129 0.011*
Hypoglycaemic event (patient-year) -0.016 -0.041 0.008 0.189
Total cholesterol (mmol/L) 0.720 0.406 1.034 \0.001*
Age 0.001 -0.017 0.020 0.882
Duration -0.006 -0.026 0.014 0.560
Post-treatment HbA1c (%) 0.002 -0.068 0.073 0.944
BMI body mass index, HbA1c glycosylated haemoglobin, CI confidence interval, coef. co-efficient, LE life
expectancy, QALY quality-adjusted life-year
* Significant at 5% level
Fig. 3 Relationship between DHbA1c and the ratio of DQALYs and
DLE, scatter and fitted regression. HbA1c glycosylated haemoglobin,
LE life expectancy, QALY quality-adjusted life-year
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modelling studies included. While we note some simula-
tion models make additional assumptions about the relative
trajectory of HbA1c, most economic evaluations of diabetes
therapies do not report these in a uniform manner and with
insufficient details to be incorporated into the current
analysis. While there is a strong association between initial
HbA1c and long-term outcomes, the consistency of
regression relationship depends on independence of the
initial HbA1c and the error term. It would be useful to re-
examine this assumption in future work, particularly as the
transparency of reporting of simulation models improves
over time.
Second, a lack of statistical power (124 pair of com-
parators) meant that we were unable to include many
variables in the multivariable regression. Although other
factors such as sex percentage, ethnicity and baseline val-
ues for other risk factors were also collected they were not
included. Further, the limited number of studies using
simulation models other than CORE meant we were unable
to investigate the consistency between models separately.
We found no evidence of heterogeneity between models by
comparing studies that used the CORE model and studies
that used any of the other type 2 diabetes simulation
models. Again, there is scope for future work to include
more control variables and further explore the consistency
between models when more studies are available.
Finally, we have not taken account of reported uncer-
tainty surrounding model estimates because of the limita-
tions in the reporting of these measures in published
studies. A future analysis could focus on comparisons of
uncertainty by different simulation models.
5 Conclusion
We found a linear relationship between the difference in
HbA1c and the difference in QALYs and LE based on
published studies using type 2 diabetes models. There was
no evidence of heterogeneity among models. When the
difference in HbA1c is small, the gain in QALYs largely
exceeds the gain in LE, suggesting when the treatment
effect on HbA1c is limited, the increase in QALYs mainly
comes from utility gain, rather than longer life-years. Our
study provides a benchmark for decision makers to identify
studies deviating from others, and potentially generate
preliminary long-term effectiveness predictions when
insufficient resources are available to use a simulation
model.
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